FDA approves 1st COVID-19 drug: the antiviral remdesivir

The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health.

Associated Press

Oct 22, 2020, 10:20 PM

Updated 1,331 days ago

Share:

FDA approves 1st COVID-19 drug: the antiviral remdesivir
U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an IV.
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health.
It had been authorized for use on an emergency basis since spring, and now becomes the first drug to win full Food and Drug Administration approval for treating COVID-19. President Donald Trump received it when he was sickened earlier this month.
Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who are hospitalized for a coronavirus infection. For patients younger than 12, the FDA will still allow the drug’s use in certain cases under its previous emergency authorization.
The drug works by inhibiting a substance the virus uses to make copies of itself. Certain kidney and liver tests are required before starting patients on it to ensure it's safe for them and to monitor for any possible side effects. And the label warns against using it with the malaria drug hydroxychloroquine, because that can curb its effectiveness.
“We now have enough knowledge and a growing set of tools to help fight COVID-19,” Gilead's chief medical officer, Dr. Merdad Parsey, said in a statement.
The drug is either approved or has temporary authorization in about 50 countries, he noted.
Its price has been controversial, given that no studies have found it improves survival. Last week, a large study led by the World Health Organization found the drug did not help hospitalized COVID-19 patients, but that study did not include a placebo group and was less rigorous than previous ones that found a benefit. The FDA's approval statement noted that, besides the NIH-led one, two other studies found the drug beneficial.
Gilead charges $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.
So far, only steroids such as dexamethasone have been shown to cut the risk of dying of COVID-19. The FDA also has given emergency authorization to using the blood of survivors, and two companies are currently seeking similar authorization for experimental antibody drugs.


More from News 12
0:26
Authorities: New Fairfield man turned off power to apartment, interfered with 'vital' medical equipment

Authorities: New Fairfield man turned off power to apartment, interfered with 'vital' medical equipment

2:11
Sunny skies, warm temperatures and breezy conditions in Connecticut

Sunny skies, warm temperatures and breezy conditions in Connecticut

3:41
‘I am different.’ How a Trumbull boy and his mom are changing curious stares into smiles

‘I am different.’ How a Trumbull boy and his mom are changing curious stares into smiles

0:46
Customers revel in Stamford's Arts & Crafts on Bedford

Customers revel in Stamford's Arts & Crafts on Bedford

0:13
Officials: Lighting strike causes fire at Bridgeport apartment building

Officials: Lighting strike causes fire at Bridgeport apartment building

2:04
Kevin Jonas undergoes surgery to remove common skin cancer; urges fans to get checked

Kevin Jonas undergoes surgery to remove common skin cancer; urges fans to get checked

Is your dad awesome? Connecticut tell us why your dad rocks!

Is your dad awesome? Connecticut tell us why your dad rocks!

2:24
Connecticut prepares for upcoming heat wave next week

Connecticut prepares for upcoming heat wave next week

2:33
SILVER LINING: Swimmer from Darien recalls tragic shark attack in Turks and Caicos

SILVER LINING: Swimmer from Darien recalls tragic shark attack in Turks and Caicos

2:35
Supreme Court bump stock ruling won't impact CT ban

Supreme Court bump stock ruling won't impact CT ban

Alex Jones’ personal assets to be sold to pay $1.5B Sandy Hook debt. Company bankruptcy is dismissed

Alex Jones’ personal assets to be sold to pay $1.5B Sandy Hook debt. Company bankruptcy is dismissed

0:14
Police: Goshen man dies after crashing into a tree in Torrington

Police: Goshen man dies after crashing into a tree in Torrington

0:45
Gov. Lamont announced over 26 million for remediation and development to properties across Connecticut

Gov. Lamont announced over 26 million for remediation and development to properties across Connecticut

0:56
 Free jazz concert for Bridgeport seniors to be held next Thursday

Free jazz concert for Bridgeport seniors to be held next Thursday

3:03
'Truly incredible.' Staples High School club 3D prints prosthetics for people in need

'Truly incredible.' Staples High School club 3D prints prosthetics for people in need

0:22
Police: Over 75 pounds of marijuana found during shooting investigation in Milford

Police: Over 75 pounds of marijuana found during shooting investigation in Milford

0:47
Michelle Troconis' family releases statement 2 weeks after her sentencing

Michelle Troconis' family releases statement 2 weeks after her sentencing

0:47
Monroe Congregational Church's 52nd annual Strawberry Festival is this weekend. Here's what you need to know!

Monroe Congregational Church's 52nd annual Strawberry Festival is this weekend. Here's what you need to know!

0:17
Officials: Connecticut diesel tax to rise 3.2 cents in July

Officials: Connecticut diesel tax to rise 3.2 cents in July

0:49
Police: Motorcyclist seriously injured in Newtown crash as motorcycle fatalities rise across the country

Police: Motorcyclist seriously injured in Newtown crash as motorcycle fatalities rise across the country